High-risk human papillomavirus (hr-HPV) E6 and E7 oncogenes are associated with resistance to radiotherapy in cervical cancer. Efforts have been taken to employ HPV E2, a crucial negative transcriptional modulator of HPV E6 and E7 oncogenes, and also an apoptosis-inducing agent, for therapeutic intervention. Despite being conceptually attractive, the potency and feasibility of current hr-HPV E2-based therapies remain limited. Here, we designed a novel recombinant adenovirus, named M5, with a 27-bp deletion in E1A conserved region-2 by which to realize tumor-specific replication, and a total HPV type 16 (HPV16) E2 gene complementary DNA inserted into the E3 coding region. In this design, M5 exploited the adenovirus E3 promoters to express HPV16 E2 gene in a viral replication-dependent manner and preferentially silenced the hr-HPV E6 and E7 oncogenes in HPV-positive cervical cancer cells. In vitro and in vivo assays confirmed that M5 exhibited potent antitumoral efficacy. Moreover, the effects of combined treatment with M5 and radiation treatment resulted in synergistically enhanced potency (Po0.01). The increase in killing efficacy of M5 was also found in HPV-negative cervical cancer cells, for which the pro-apoptotic activity of HPV16 E2 was thus responsible. Our results indicated that the use of M5 that locally delivers HPV16 E2 to cancers has broad therapeutic windows and that the combination therapy with radiation for cervical cancer will be the more effective way of improving survival.
Introduction
Despite advances in the treatment modalities, cervical cancers (CCs) are still the second leading causes of cancer death among women worldwide. 1 Radiation treatment is one of the most standardized and effective modalities for contemporary cervical carcinoma therapy besides the principal radical hysterectomy. 2 Owing to the increased risk of complications in nearby critical structures, the amount of irradiation that can be delivered is limited and dose escalation is likely not the total solution to radiation resistance. 3 These facts underscore an urgent need for the development of more effective and less toxic novel therapeutic approaches. Therefore, investigators have turned to strategies for sensitizing CCs to radiation, and gene therapy represents one such modality.
Radiation therapy (RT) for cancer induces cell death by apoptosis, which has been regarded as a prognostic indicator for RT in cervical carcinoma. 4 Apoptosis deficiency, especially induced by the inactivation of the initiator caspase (caspase-8), possibly contributes to the marked resistance of cancer towards RT. 5 In addition, there is considerable evidence showing that high-risk human papillomaviruses (hr-HPVs) are the principal cause of invasive CCs. 6 Hr-HPVs are thought to cause the carcinogenesis of CC through the binding and inactivation of tumor suppressors, p53 7 and retinoblastoma (Rb) protein, 8 by the viral-transforming protein E6 and E7, respectively. Radiation can enhance the expression of HPV type 16 (HPV16) E6 and E7 oncogenes in human CC, which may be the likely reason for radiation resistance in HPV-associated CC. 9 HPV E2 protein, an early protein encoded virally, has been shown as a transcriptional regulator. 10 Binding of E2 to sites near the constitutive early promoter of hr-HPVs can negatively regulate the expression of E6 and E7, leading to cell cycle arrest and the efficient immortalization of primary human keratinocytes. On the other hand, HPV E2 is also involved in the induction of apoptosis. Some groups have found that E2-induced apoptosis is detected not only in HPV-positive, but also in HPV-negative carcinoma cell lines, even in primary epithelial cells, 11, 12 and E2 sensitized cells to apoptosis mainly via activation of caspase-8. 13 These properties have made E2 protein a putative tool of experimental therapeutics.
Oncolytic adenoviruses (Advs) are biological antitumor agents that offer a number of attractive features both as a treatment modality and a vector for gene delivery. 14, 15 The most studied oncolytic Adv, so far named onyx-015, 16 is an Adv with the E1B 55 kDa gene deleted. However, onyx-015 has demonstrated only limited antitumoral efficacy, as the deletion of E1B 55 kDa conferring tumor selectivity also reduces the potency of the viral replication in tumors. 17 More recently, it has been reported that dl922-947 (also known as D24), an Adv type 5 (Adv5) mutant with a 24-bp deletion in the E1A protein conserved region-2 (CR2), has much improved antitumoral efficacy over that of onyx-015 while retaining tumor selectivity. 18, 19 In addition to optimizing oncolytic Adv per se, incorporation of therapeutic transgenes into oncolytic virus was expected to augment antitumoral efficacy. For insertion of transgene, Hawkins et al. 20 have recently developed a novel gene delivery system by replacing E3 6.7K/gp19K of wildtype Adv5 (wt-Adv5) with a therapeutic gene. The transgene in this system can be efficiently expressed by native Adv E3 promoters at a level superior to that of the human cytomegalovirus major immediate early promoter/enhancer. More importantly, expression of the transgene is dependent on active viral DNA replication. 20 Such Ads vectors have entered clinical trials where their advantages including combination with radiotherapy or chemotherapy to increase therapeutic efficacy and potentially decrease toxic side effects have been demonstrated. 21 In this study, we constructed and characterized a novel E1A CR2-deleted Adv5, named M5, with the whole open reading frame (ORF) of HPV16 E2 gene inserted into the deleted 6.7K/gp19K region to establish a selectively replicative Adv-mediated gene therapy strategy for CC. Careful assessment was made for specific targeting of tumor cells by HPV E2 gene and the synergistic efficacy of combined treatment with M5 and radiation treatment.
Materials and methods

Viruses and cells
Wt-Adv5 was obtained from American Type Culture Collection (ATCC, Rockville, MD). Adv5/dE1A with a 27-bp deletion from wt-Adv5 bases 920-946 in E1A CR2 was constructed previously. 22 M5 was driven from Adv5/ dE1A through replacement of the 6.7K/gp19K ORF in the E3 region by the subcloned HPV16 E2 coding sequence (amplified from the plasmids containing cloned full-length genomic DNA of HPV16, kindly provided by Dr EthelMichele de Villiers, University of Heidelberg, Heidelberg, Germany). Adv5/dE1A/6.7K-gp19K, driven from Adv5/ dE1A through deletion of the 6.7K/gp19K ORF, and Adv-TK, the replication-defective Adv mutant as our previous description, 23 were used as vector controls for M5. The viral mutants were constructed by homologous recombination in the human embryonic kidney 293 cells.
The following human CC cell lines varying in HPV infection and pathologic types were obtained from ATCC: SiHa (HPV16-positive, squamous carcinoma), HeLa (HPV18-positive, adenocarcinoma) and C33A (HPV-negative, squamous carcinoma). Cells were grown in Dulbecco's modified Eagle's medium with 10% fetal bovine serum. Lung-derived primary human microvascular endothelial cells were purchased from Cambrex Bio Science Rockland (Rockland, ME) and cultured according to the manufacturer's instructions and previous description. 24 Verification of M5 by ClaI restriction mapping The 293 cells were infected with M5 at a multiplicity of infection (MOI) of 10. After 72 h of culture, 293 cells were collected for isolation of viral genome DNA. In all, 2 mg of virus DNA were digested with ClaI and separated on a 0.8% agarose gel.
In vitro cytopathic effect and viral replication assays
The viral cytopathic effect (CPE) and replication assays were performed as described elsewhere. 18 To assess Adv replication-dependent cell killing effect, cells were grown to 70% confluence in six-well plates and infected with M5, Adv-TK or wt-Adv5 for 90 min at indicated MOI. For CPE assays, the plates were stained with 0.1% crystal violet (Sigma Chemical, St Louis, MO) in 20% ethanol. For viral replication assays, cells were infected at an MOI of 5 with various viruses. After 48 h, both cells and supernatants were collected, and the cell lysates were prepared by three cycles of freezing and thawing and titered on 293 cells using the TCID 50 method according to the instructions in the AdEasy application manual (Quantum Biotechnologies, Montreal, Canada). Results are the mean of three replicates presented as plaqueforming units (PFU). For assessment of the radiation on virus yield, SiHa cells were irradiated with a dose of 0-10 Gy, and then infected with M5 at an MOI of 0.01, 0.1 or 1 PFU per cell at 24 h post-irradiation. 0 ) for GAPDH gene were used. Following the polymerase chain reaction (PCR) reaction, a melting curve assay was carried out to determine the purity of the amplified product. Threshold cycle value (CT) is given for each sample and indicates the cycle at which a statistically significant increase in fluorescence was first detected. These values were then normalized by the average expression of GAPDH to determine ratios of relative expression.
Reverse transcription-PCR
Western blotting
The total protein used for western blotting was prepared using M-PERt mammalian protein extraction reagent (Pierce, Rockford, IL). Pretreated cells were pelleted by centrifugation at 2000 g for 10 min. M-PERt reagent was added to the cell pellet containing protease inhibitor cocktail (Sigma Chemical) and gently mixed for 10 min. Cell debris was removed by centrifugation at 27 000 g for 15 min. Protein concentration was determined using the Bradford assay (Bio-Rad, Hercules, CA). A portion of total protein was subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Protein was transferred to nitrocellulose membranes, which were blocked with phosphate-buffered saline (PBS) containing 5% non-fat milk for 1 h and then incubated with 1 mg ml À1 specific antibody at 4 1C overnight. After washing with TBST (0.1 M Tris-HCl, pH 7.5; 0.9% sodium chloride; 0.05% Tween-20) for 4 Â 15 min, filters were incubated with 1:5000 horseradish peroxidaselabeled second antibody for 1 h at room temperature and washed with TBST for 4 Â 15 min. Immunodetection was performed using SuperSignal West Femto Maximum Sensitivity Substrate (Pierce). Second antibody and antibodies to HPV16 E6, HPV18 E6/E7, cytokeratin 19 and b-actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA), antibody to HPV16 E7 from NeoMarkers (Fremont, CA) and antibody to caspase-8 from Sigma.
Apoptosis detection CC cells (SiHa, HeLa and C33A) and microvascular endothelial cells (non-proliferative or proliferative) were infected with M5 at an MOI of 1 and cultured for another 24 h. Adv5/dE1A, Adv5/dE1A/6.7K-gp19K and Adv-TK were included as controls. Cells were then exposed to irradiation at a dose of 0-10 Gy and maintained in complete medium for another 48 h with CC or 24 h with microvascular endothelial cells. Pretreated cells were resuspended in binding buffer containing 10 mM HEPES, 140 mM NaCl and 2.5 mM CaCl 2 at a density of 1 Â 10 6 cells per ml. A measure of 5 ml portion of FITC plus Annexin V (BD Pharmingen, San Jose, CA) and 10 ml of propidium iodide (PI) solution at a concentration of 50 mg ml À1 in PBS was then added, and the cells were incubated for 20 min at room temperature in the dark. Stained cells were subsequently observed under confocal laser scanning microscopy with a 488 nm argon-ion laser (LSCM, German Leica, TCSSP) and analyzed using a FACSort Flow Cytometer (Becton Dickinson, San Jose, CA). The CELLQuest software was used for acquisition and analysis of data.
Quantitative cytotoxicity and cell viability assays Quantitative cytotoxicity and cell viability assays were performed using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide method. Cells were plated in 96-well tissue culture plates and grown to 70% confluence. For quantitative cytotoxicity assays, cells were infected with M5 at an MOI of 0.1-1000. For cell viability assays, cells were infected with Adv mutants at an MOI of 1. After 72 h, the cells were stained with 5 mg ml À1 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide reagent (Sigma). Absorbance of each well was measured at a wavelength of 570 nm and the growth suppression rate was calculated using the following formula: growth suppression rate (%) ¼ (1À(A 570 of experimental wells/A 570 of mock control wells)) Â 100%. Each assay was performed in triplicate.
Mouse tumor model studies All animal procedures were performed in the animal facility in accordance with applicable animal welfare regulations under an approved Institutional Animal Care and Use (IACUC) protocol and study design. Female athymic Balb/c nu/nu mice (4-6 weeks old) (obtained from the Animal Experimental Center of Slaccas, Shanghai, China) were implanted subcutaneously in the right flank with 2 Â 10 6 SiHa cells mixed with an equal volume of Matrigel (BD Matrigel Matrix; BD Biosciences, San Jose, CA) using manual restraint. Once tumors have grown to 100 mm 3 in volume, mice were randomly sorted into groups (n ¼ 12 for each group). Total body irradiation was performed once on day 0 at a dose of 5 Gy (maximum-tolerated dose) and the intratumoral injection of virus delivery was selected because the uterine cervix is readily accessible to an intralesional administration approach without invasive techniques and systemic administration of truly tumor-selective oncolytic viruses. For combined treatment studies, animals bearing SiHa xenografts received 5 Gy irradiation and intratumoral injections of 1 Â 10 8 PFU M5 for 5 consecutive days. The first virus injection was performed 6-7 h following irradiation in anesthetized animals. Different sites of the tumor were chosen for each injection. Simultaneously, groups of animals were either irradiated with 5 Gy and injected with Adv5/dE1A or PBS for 5 days, or were enclosed in a radiation chamber without radiation and received injections of 1 Â 10 8 PFU M5 or Adv5/dE1A, respectively, for 5 days, or control animals were enclosed in the radiation chamber without radiation and were injected with PBS in an equivalent volume and schedule. All animals were observed daily, throughout the study, for food and water consumption, appearance and body condition. Body weights were monitored twice a week. Tumors were measured in three dimensions by external caliper twice a week, and the volumes estimated by the formula (length (mm) Â width (mm) Â height (mm))/2, until the mice were killed (tumor volume 41000 mm 3 or 80 days after the initiation of treatment). Mean tumor volume for each treatment group±s.e of the mean was plotted versus day after virus injection. Two parallel experiments, immunohistochemistry for HPV16 E6, E7 protein and TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP-biotin nickend labeling) analysis for apoptosis detection, were performed with tumor sections of the mice killed 30 days after treatment.
Immunohistochemical analysis
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue sections, as described previously, 25 to detect HPV16 E6, E7 protein expression. Mouse anti-HPV16 E6 monoclonal antibody was purchased from Santa Cruz Biotechnology and antibody to HPV16 E7 from NeoMarkers. The positive cells were stained brown under the microscope.
In situ TUNEL assay For detecting apoptotic cells, the sections were analyzed by TUNEL assay by using the In Situ Cell Death Detection Kit (Boehringer Mannheim, Germany) according to the manufacturer's instructions. Briefly, the slides were treated with 3% H 2 O 2 , and then covered with 1 ml each of terminal deoxynucleotidyl transferase and digoxigenin-labeled dUTP in 20 ml terminal deoxynucleotidyl transferase buffer at 37 1C for 2 h. Cells were subsequently reacted with biotin-labeled anti-digoxigenin for 30 min at 37 1C, followed by washing in PBS. Next, the slides were incubated with an avidin and biotinylated horseradish peroxidase macromolecular complex and stained with diaminobenzidine. Finally, the slides were counterstained with hematoxylin. The apoptotic cells were stained brown under the microscope.
Statistical analysis
The cell culture data from at least three independent experiments were expressed as means±s.d. and examined by one-way analysis of variance, followed by the StudentNewman-Keuls test. For in vivo data, the significance of differences was determined with the log-rank test and the difference in relative tumor volume was compared using the type 2 (two-sample equal variance), two-tailed t-test. All P's were two-sided and values o0.05 were considered significant. The SPSS v.12.0 software package was used for all statistics.
Results
Construction and confirmation of M5
M5 had two artificial modifications compared with wtAdv5 genome (Figure 1a ). First, a 27 bp sequence from wt-Ad5 bases 920-946 was deleted to generate Adv5/ dE1A, which expresses a mutant E1A protein lacking the CR2 domain necessary for pRb binding. Second, the E3 transcription unit of the Adv5/dE1A genome, corresponding to wt-Adv5 bases 28 530-29 360 known to encode E3 6.7K and gp19K protein, was selectively excised and substituted by a fragment of a sense HPV16 E2 coding sequence cDNA with a ClaI restriction site introduced at each end to generate M5. In M5, HPV16 E2 cDNA was fused to the 5 0 portion of the E3 ADP gene and transcribe a single chimeric transcript, which was detected in C33A cells 24 h after being infected with M5 at an MOI of 5 ( Figure 1c) . Expression of HPV16 E2 cDNA in M5 mimics the expression kinetics of the native E3 6.7K and gp19K gene and depends strongly on viral DNA replication. The genomic structure of M5 was further verified by restriction digest with ClaI, and the appearance of a 1.1 kb-long band confirmed the insertion of HPV16 E2 ORF and deletion in the E1A region (Figure 1b) . Using the AdenoEasy system, other studies 26 have also constructed an adenoviral vector containing HPV16 E2 gene under the control of the cytomegalovirus promoter recently. However, the AdenoEasy vector, containing wt-Adv5 genome deleted for E1 and E3 regions, is replication-defective and has no power for tumor selectivity. yielded complete lysis at low MOI irrespective of the HPV infection and pathology status. The CPE potency of M5 was 1-100 times lower than that of wt-Adv5, depending on the cancer cell line tested. Wt-Adv5 caused complete CPE at an MOI of 0.1 in non-proliferating primary normal cells (that is, Q-MVEC). In contrast, M5 could not yield measurable CPE at an MOI of 0.1-100 and replication-deficient cells showed no detectable CPE at an MOI below 100. Even in proliferating MVECs (that is, P-MVEC), a 5000-fold higher MOI exhibited only 10% CPE. The restriction of replication of M5 to CC cells was further confirmed by transcript levels of viral fiber, a late structural viral gene whose expression is dependent on active viral replication. Unlike Adv-TK-infected cells, fiber transcripts were readily detected in M5-infected SiHa cells 24 h after infection, at levels similar to those obtained with wt-Adv5 infection. In contrast, fiber transcripts were undetectable in M5-infected Q-MVEC, indicating lack of the replication of M5 in Q-MVEC (Figure 2b) . Next, we directly measured viral production of M5 in a panel of CC and normal cells by in vitro viral replication assays. As shown in Figure 2c , M5 selectively replicated in CC cell lines, but not in Q-MVEC and P-MVEC, when compared with both Adv-TK and wt-Adv5 (Po0.01).
M5 selectively depleted HPV16 E6, E7 proteins in CC cells
The abundance of 14.7K mRNA from M5 was similar to that from wt-Adv5 in HeLa and SiHa, indicating that E3 promoter was highly active in cancer cells. In Q-MVEC, however, the 14.7K mRNA was undetectable, indicating lack of E3 promoter activity (Figure 3c) . We also performed a time-course experiment in M5-infected SiHa cells in the presence or absence of arabinofuranosylcytidine, an inhibitor of viral DNA replication, to confirm the dependence on viral DNA replication of HPV16 E2 expression. Although we detected a low expression of HPV16 E2 cDNA/ADP fusion mRNA at early time (12 h post-infection), addition of arabinofuranosyl-cytidine reduced the expression of fusion mRNA when viral DNA replication was attenuated at late times (24, 36 and 48 h post-infection), as shown in Figure 3d .
M5 showed superior antitumor efficacy and selectively activated caspase-8 in CC cells To evaluate the therapeutic benefits of M5, a panel of CC cells (SiHa, HeLa and C33A) was infected with various virus mutants at an MOI of 1 and cultured for 24 h. We observed the staining of Annexin V/FITC and PI 72 h after transfection to determine whether M5 can facilitate apoptosis. Confocal scanning laser microscope showed typical apoptotic morphology in M5-transfected SiHa cells (Supplementary Figure S1) . The result was consistent with the analysis by flow cytometry detecting PI staining. The apoptosis rates detected by flow cytometric (FCM) in M5-transfected SiHa and HeLa, both HPV-positive cancer cells, were much higher than that in Adv-TK or Adv5/dE1A-transfected ones (Po0.01). In HPVnegative CC cell line C33A, they also exhibited augmented apoptosis when transfected with M5 compared to Adv-TK or Adv5/dE1A. We have previously reported that HPV16 E2 abrogate the apoptosis-inhibitory function of c-FLIP in C33A and render the cell hypersensitive to the Fas/Fas ligand apoptotic signal even below threshold concentration, 27 which is nothing to do with HPV E2 gene in synergistic enhancements of antitumor efficacy W Wang et al the transcriptional repression of HPV E6 and E7 expression by HPV E2. Therefore, the pro-apoptotic function of HPV16 E2 was thus responsible for the increase in efficacy of killing. On the contrary, M5 did not significantly induce Q-MVEC or proliferating MVEC apoptosis and featured a good therapeutic window ( Figure 4a ). As depicted in Figure 4b , the quantitative 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay also showed that M5 preferentially inhibited the growth of CC cells, but not normal cells with a dose-dependent tendency. Moreover, the growthinhibition efficiency of M5 was more distinct than that of Adv5/dE1A. Because M5 fused HPV16 E2 ORF directly to the ADP gene, we next measured the levels of ADP expressed from M5 and Adv5/dE1A/6.7K-gp19K versus Adv5/dE1A to clarify if increased killing by M5 resulted from altered expression of the ADP gene (Figure 4c ). We realized that checking for ADP protein would be the most straightforward experiment to address the concern. As the antibody against ADP protein was not commercially available, we thus used quantitative real-time PCR as an alternative approach. ADP protein was encoded by two types of spliced transcripts that shared the same middle exon (y-leader) and coding portion. 28 The use of a sense primer from the y-leader and antisense primer to the coding portion would amplify total mRNA for translation of ADP protein. In SiHa cells, the level of ADP mRNA from Adv5/dE1A/6.7K-gp19K was higher than that from Adv5/dE1A, which was in accord with that reported by Doronin et al. 29 Nevertheless, the level of ADP mRNA from M5 was similar to that from Adv5/ dE1A (P40.05), indicating that insertion of HPV16 E2 cDNA did not affect ADP expression. We also investigated the mechanism of M5 on the modulation of molecules involved in the apoptotic pathway by quantifying the caspase-8 activity using the Caspase-8 Colorimetric Assay Kits (BD Pharmingen). Although caspase-8 activity was nearly undetectable in Adv-TK-infected SiHa cells 24 h after incubation, given their lack of viral replication, in Adv5/dE1A-infected SiHa cells, it was detected at levels much lower than that obtained with M5 infection (Po0.01; Figure 4e ). In Q-MVEC, activation of caspase-8 of M5 was also much lower than that in SiHa cells (Po0.01), indicating lack of replication of M5 in Q-MVEC. Here, we also observed the hyperactivation of caspase-8 not only in M5-infected SiHa and HeLa cells, but also in HPV-negative C33A cells. The result was exteriorly confirmed by the cleaved caspase-8 protein detection using western blot (Figure 4d) , which was in accord with our previous report. To determine the impact of radiation on viral replication, viral burst size (yield) assay was performed on SiHa cells. The cells were infected with M5, exposed to radiation and harvested at various time points after infection. As shown in Figure 5b , at day 2 post-infection, the viral yields were similar in irradiated and nonirradiated M5-infected cells. However, at later time points the virus yields were much higher in cells that were irradiated than in cells that were not irradiated (Po0.05). Replication of M5 reached a plateau at day 6 in irradiated SiHa cells and at day 8 in non-irradiated cells. These results suggest that treating the infected cells with radiation enhances the replication of M5.
Effect of combination of M5 and radiation on tumor growth in vivo
To evaluate the benefits of expression of HPV16 E2 in vivo, we subsequently assessed the antitumor efficacy of M5 versus Adv5/dE1A as a single agent in female athymic BALB/c mice bearing subcutaneous SiHa CC cells. In agreement with in vitro findings, consequent reduction of HPV16 E6, E7 protein became evident after direct intratumoral injection of M5, but not other virus mutants. TUNEL assay was used to visualize DNA fragmentation at the single-cell level. As shown in Figure 6a , more apoptotic cells were observed in the tumor xenografts of M5-treated group than in those of To demonstrate additive or synergistic effects, we next compared the antitumor potency of M5 with other Adv mutants in combination with radiation. A significant decrease in tumor volume between controls and all treatment groups was observed (Figures 6b and c) . Although a single treatment with either M5 or radiation was effective in inhibiting tumor growth, the combination of the two resulted in significant tumor regression. At day 20 after treatment, the average tumor volume of the group treated with M5 was 278% of baseline, and the tumor volume of the group treated with radiation alone was 250% of baseline. However, when the identical dose of M5 was followed at 24 h by the identical dose of radiation, a statistically significant drop in the relative tumor volume to 95% of baseline was observed at this time point (Po0.01; Figure 6c ). Kaplan-Meier analysis also showed that M5 transfection could improve the survival of tumor-bearing mice in combination with radiotherapy, which is much superior to that of those treated by Adv5/dE1A plus radiation or M5 alone (Po0.05; Figure 6d) . Tolerability of the virus and/or radiation treatment was monitored by body weight measurements. Animals treated with both M5 and radiation gained more weight than those treated with M5 or radiation alone (Figure 6e ). The combination treatment was also found to protect the animals from the transient weight loss that was observed in animals treated with M5 or radiation alone.
Discussion
Infection with hr-HPV, particularly the HPV type 16 (HPV16), is causally linked to the development of CC worldwide. Rationale in the development of novel treatment strategies for HPV-associated cancers is targeting on the basis of the presence of HPV in malignant cells. 30 Disruption of the E2, as a consequence of the integration of the viral DNA into the cellular genome gene, is associated with malignant transformation and progression. 25 This mechanism occurs in human cell lines derived from HPV-positive cervical carcinoma (HeLa, SiHa and CaSki), and there is a clear correlation between the disruption of the E2 gene and the increased expression of the E6 and E7 oncogenes in the development of the transformed phenotype.
6,10-13 Bermu´dez-Morales et al. 26 have reported that the E2 protein not only is an efficient repressor of the E6 and E7 oncogenes, but also induces apoptosis in human and murine HPV16-transformed cells and has antitumoral effects in vivo. These results highlight the clinically relevant therapeutic target derived from the possible use of the HPV E2 for the prevention and treatment of CC. However, these effects of E2 had not been documented in HPV-negative CC and the possibility for development of a novel vector for effective gene therapy with low toxicity in clinical application had not been examined previously.
Oncolytic viral therapy, the use of genetically engineered viruses that specifically target and destroy tumor cells via their cytolytic replication cycle, offers a promising new platform for selective cancer treatment. Much of this work has been carried on in Advs, 31 which can also function as therapeutic gene delivery vehicles. Addition of an adjuvant therapeutic transgene could augment killing the infected tumor cells as well as non-infected tumor cells nearby by the newly released progeny. 32 We have previously reported a series of novel oncolytic adenoviral mutants in which we replaced the 6.7K/gp19K region with a fragment of antisense cDNA of a target gene in an E1A CR2 region-deleted adenoviral mutant called Adv5/ dE1A. 22, 33 The strategy of combining the oncolytic ability with the benefits of gene silencing has proven to be effective and has the potential to be generally applicable in a wide range of molecule-based anticancer therapeutics. In this study, we developed a novel oncolytic Adv M5 as a potent antitumoral strategy for the treatment of CC. To increase the potency of M5 beyond the direct killing of infected tumor cells, we armed it with HPV16 E2, thereby creating a dual oncolytic and HPV E2 gene therapy delivery Adv. We show that M5 exhibits viral replication and downregulation on hr-HPV E6, E7 expression in CC cells. Treatment of established human CC xenografts with M5 led to a strong and sustained antitumor response characterized by widespread viral replication, profuse apoptosis and remarkable growth suppression. This is the first study demonstrating that expression of HPV16 E2 by an oncolytic Adv in cervical malignancy leads to a potent antitumor response.
Wt-Ad5, a replication-competent Adv without tumorselective action, could not be used in a patient owing to systemic toxicity to normal cells/tissues and represents an important benchmark in our studies. The aim of armed oncolytic Advs should be to have tumor-selective action, yet display antitumor potency similar to or better than that of wild-type Adv without increasing toxicity. The replicative capacity of M5 in vitro was attenuated 1-to 100-fold compared with wt-Ad5, depending on the cell line tested (Figure 2) . The reasons for this are currently unknown but may in part relate to differences in the E3 gene region between the two viruses. 34 Despite this, M5 was able to induce effectively cytolysis in vitro, and most importantly, the reduced toxicity of M5 compared with wt-Adv5 is most evident in vitro against infected normal cells. Our present data had validated an interesting approach to preferentially target the tumor cells while sparing normal cells unaffected.
Despite E1A deletion, another bioengineering component in M5 was the insertion of HPV16 E2 gene into the E3 6.7K/gp19K region. Our experiments verified the specific inhibition of HPV E6, E7 expression in M5-transfected SiHa and HeLa cells, which was in accordant with the transcriptional function of HPV16 E2. And this result was in accord with our previous study using another E1A mutant Adv with antisense HPV16 E6 E7 DNA inserted into the same 6.7K/gp19K region. 33 To more thoroughly evaluate the potential therapeutic benefit of M5, we compared it in parallel to its parental generation Adv5/dE1A and Adv5/dE1A/6.7K-gp19K. Although deletion of the E3 6.7K/gp19K region, which have antiapoptotic and immunity-evading function as reported, 35, 36 could enhance antitumor efficacy versus Adv5/dE1A (Figure 4a) , the tumoricidal effect of M5, characterized by apoptosis rate and cell viability, is still superior to that of Adv5/dE1A/6.7K-gp19K. Most strikingly, the tumoricidal effect of M5 exhibited not only in SiHa and HeLa cells, but also in HPV-negative CC cell lines C33A apparently. The remarkable increase of caspase-8 activity was detected in all these cells, which was consistent with the potent antitumor activities of HPV16 E2 mediated by its strong pro-apoptosis functions triggering of death receptor signaling of apoptosis 12, 13, 27 and showed that M5 represents a significant advancement compared with its first-generation and previous oncolytic Adv with antisense HPV16 E6 E7. 33 This result prompted that M5 might have the potentiality for widespread use in cancer treatment owing to its board-spectrum apoptosis inducibility.
Surgery and RT are the two most commonly used therapeutic modalities for localized CCs. However, a narrow therapeutic window coupled with limiting highdose toxicity of RT restrains its effectiveness. One approach to increase therapeutic efficacy and potentially decrease toxic side effects is combination therapy. The mode of action of radiation, chemotherapy and virotherapeutic agents is different and would not be expected to lead to the development of cross-resistance. 21 Thus, combination treatment has great potential for translation into effective clinic therapy in the immediate future. In this study, the combination of M5 and radiation resulted in a synergistic increase in cell killing activity in vitro compared to that resulting from treatment with either agent alone. The combination of M5 and radiation did not lead to any significant change in specificity and selectivity of the oncolytic virus relative to M5 in singleagent experiments. In addition, the virus yields were much higher from SiHa cells that were irradiated than from cells that were not irradiated. The mechanisms involved in enhanced uptake of Adv following ionizing radiation are not fully understood currently. Changes caused by radiation both at the cell surface and in the cytoplasm and nucleus may all contribute to improved virus uptake by tumor cells. 37 The synergistic cytotoxicity was also observed in the in vivo SiHa xenograft model: combination of 1 Â 10 8 PFU M5 with RT significantly inhibited the tumor growth and increased the survival probability compared to either agent alone. Moreover, in the combination group, no significant body weight loss was observed. These results show that M5 in combination with radiation has an improved oncolytic activity at lower doses and with no added toxicity.
In summary, our investigations demonstrate the potentiating antitumour efficiency of local treatment with a dual oncolytic and HPV16 E2 gene therapeutic Adv M5 in combination with RT for human CC. Our current findings with M5 clearly show that the virotherapy and radiation combination significantly improves both cytotoxicity in vitro and efficacy in the xenograft tumor model in vivo, but without a concomitant increase in toxicity. Although a number of efficacies, safety and manufacturing issues remain to be determined for the development of oncolytic Adv as antitumoral agents, the therapeutic potential of this replication-selective Adv and its combination with radiation holds promise as new treatment paradigm for CC.
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